|
|
View Clinical Trial (Medical Research Study)
|
A Study of Actonel for the Prevention of Bone Loss - NCT00452439-77030 (Clinical Trial 166636)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy166636.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Houston |
|
State:
|
|
TX |
| Zip Code: |
|
77030 |
| Conditions: |
|
Leukemia - Lymphoma |
| Purpose: |
|
The goal of this clinical research study is to learn if Actonel (risedronate) can help to
prevent the development of osteoporosis (brittle and weak bones) caused by the steroid
medication used to treat leukemia. The safety of this treatment in patients with Acute
Lymphocytic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) will also be studied.
|
| Study summary: |
|
One of the side effects of using high dose corticosteroids for the treatment of ALL is
osteoporosis. Risedronate is a medication that was designed to help prevent osteoporosis
(brittle and weak bones).
Before treatment you will receive a complete physical exam. You will have around 1
tablespoon of blood drawn for blood tests (these tests are in addition to the routine blood
tests you will have as part of the treatment for leukemia). You will have a urine sample
collected for routine tests. You will also have a bone mineral density test. This test
measures the density of the bones in your spine, hip, and total body. The test is similar
to having x-rays of your bones taken.
You will be randomly assigned (as in the toss of a coin) to one of two treatment groups.
Participants in the first group will be given risedronate (once per week), vitamin D (once
per day), and calcium (once per day). All three medications are pills and will be taken by
mouth. Participants in the second group will be given placebo (once per week), vitamin D
(once per day), and calcium (once per day). All three medications are pills and will be
taken by mouth. A placebo is a substance that looks like the study drug but has no active
ingredients. Neither you nor your doctor will know to which group you are assigned.
However, if it is needed for your care, the information will be given to your doctor.
Participants in both groups will continue to receive chemotherapy during this study as
scheduled. During chemotherapy, you will have around 1 tablespoon of blood drawn every 1-2
weeks for routine blood tests (as part of the standard of care for your treatment of
leukemia).
For this study, you will have urine samples collected and repeat bone mineral density tests
6 months, 12 months, 18 months, and 24 months after starting the study drug (or placebo).
If you develop intolerable side effects from the risedronate you will be taken off the
study.
This is an investigational study. Risedronate is FDA approved and commercially available.
Up to 80 eligible patients will take part in this study. All will be enrolled at M. D.
Anderson. |
| Criteria: |
|
Inclusion Criteria:
1. Age greater than or equal to 18 years
2. Newly diagnosed ALL or LL receiving chemotherapy with augmented BFM, Hyper-CVAD or
any variant of hyper-CVAD.
3. Female patients of childbearing potential (i.e. no hysterectomy, no loss of menses
for 12 consecutive months), must be willing to use contraception.
4. Negative pregnancy test in female patients.
5. Patients must be enrolled within 6 weeks of starting induction chemotherapy.
Exclusion Criteria:
1. Hypocalcemia of less than 8.4 (corrected to account for the albumin level, [see
Appendix E for formula])
2. Hypersensitivity to risedronate or other bisphosphonates
3. Inability to sit or stand upright for at least 30 minutes
4. Bone density T-score of -2.5 S.D or less.
5. Renal insufficiency (calculated creatinine clearance <30cc/min,[see Appendix F for
formula])
6. Patients with a 25-hydroxyvitamin D concentration of less than 20 ng/ml and evidence
of osteomalacia (low ionized calcium and high intact PTH).
7. Concomitant use of bisphosphonates, calcitonin, anabolic steroids, or fluoride.
8. Corrected calcium above 10.2, due to a cause not related to leukemia/lymphoma (i.e.
hyperparathyroidism, multiple myeloma). |
|
|
|
| Study is available at: |
|
U.T.M.D. Anderson Cancer Center
Houston, TX 77030
United States
Primary Contact:
Maria E. Cabanillas, MD
Phone: 713-745-0654 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
November 16, 2009 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|
|
|
|